<DOC>
	<DOC>NCT02520752</DOC>
	<brief_summary>Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors</brief_summary>
	<brief_title>A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patients must have: advanced solid tumors and have confirmed cMET dysregulation at least one measurable lesion as defined by RECIST 1.1. recovered from all toxicities related to prior anticancer therapies adequate organ function ECOG performance status (PS) of 0 or 1 Patients must not have: known hypersensitivity to any of the excipients of INC280 or to benzodiazepines or known intolerance and hypersensitivity to caffeine symptomatic central nervous system (CNS) metastases who are neurologically unstable presence or history of carcinomatous meningitis history of another primary malignancy that is currently clinically significant or currently requires active intervention Clinically significant, uncontrolled heart diseases, including QTcF ≥ 450 ms (male patients), ≥ 460 ms (female patients) on the screening ECG Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 Major surgery within 4 weeks prior to starting INC280 Patients receiving unstable or increasing doses of corticosteroids. Impairment of GI function or GI disease that may significantly alter the absorption of INC280 Patients who have received or consumed, or are expected to receive or consume midazolam or caffeinecontaining products (e.g., tea, coffee, cola), within 2 days prior to Day 1 and during the whole duration of the DDI phase (i.e., from Day 2 to Day 12) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cMET, INC280, caffeine, midazolam</keyword>
</DOC>